Leukemia & Lymphoma最新文献_第6页

FAS mutation varies in EMZL of different sites. FAS突变在不同位点的EMZL中存在差异。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-27 DOI: 10.1080/10428194.2026.2707443

Keying Chen, Maria-Myrsini Tzioni, Zi Chen, Ewelina Madej, Ming-Qing Du

引用次数: 0

Recurrent +8 and +9 chromosomes in intestinal Behçet's disease associated with myelodysplastic syndrome. 与骨髓增生异常综合征相关的肠behet病复发性+8和+9染色体

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-18 DOI: 10.1080/10428194.2026.2718435

Zhan Su, Wei Xu, Yan Li

引用次数: 0

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019. 2000-2019年巴西<s:1>圣保罗州儿童白血病死亡率分析

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-05 DOI: 10.1080/10428194.2026.2691908

Daniela Tibiriçá Dos Reis, Emilli Freitas Silvestri, Eduardo Jamil Farah de Oliveira, Marcela Chiedde, Edigê Felipe de Sousa Santos, Hugo Macedo, Márcia Kiyomi Koike, Maurício Giusti Calderon

{"title":"Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.","authors":"Daniela Tibiriçá Dos Reis, Emilli Freitas Silvestri, Eduardo Jamil Farah de Oliveira, Marcela Chiedde, Edigê Felipe de Sousa Santos, Hugo Macedo, Márcia Kiyomi Koike, Maurício Giusti Calderon","doi":"10.1080/10428194.2026.2691908","DOIUrl":"10.1080/10428194.2026.2691908","url":null,"abstract":"Childhood leukemia is the leading cause of cancerrelated death among children. In Brazil, limited data on pediatric leukemia trends hinder public health strategies. This study analyzed leukemia mortality in individuals aged 0-19years in São Paulo State, Brazil, from 2000 to 2019. An ecological time-series design was applied using official Mortality Information System (SIM/ DATASUS) microdata, identifying leukemia cases through ICD-10 codes C91-C96. Mortality trends were assessed using the Prais- Winsten regression model and Durbin-Watson test, estimating annual percent change (APC) and 95% confidence intervals. Between 2000 and 2019, 3687 deaths occurred (24.34/100,000), with a decreasing trend (APC: -0.017), from 1.69/100,000 in 2000 to 1.21/100,000 in 2019. Mortality was higher among males (56%), white individuals (71%), and adolescents aged 15-19years (30.8%). Acute lymphoblastic leukemia (C910) accounted for 50.8% of deaths, and unspecified septicemia (A419) was the most frequent associated cause (25.8%). SIGNIFICANCE STATEMENT Analyzing pediatric leukemia mortality trends in São Paulo state provides valuable epidemiological evidence to support surveillance, guide public health policies, and identify regional disparities. As one of Brazil's main referral centers, São Paulo offers important insights into the impact of demographic, socioeconomic, and healthcare factors on mortality, contributing to improved prevention and management strategies nationwide.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2235-2243"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fatal differentiation syndrome-associated myocarditis caused by PML: RARα-positive neutrophils in acute promyelocytic leukemia. 急性早幼粒细胞白血病中rar α阳性中性粒细胞引起的致死性分化证相关性心肌炎。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-06 DOI: 10.1080/10428194.2026.2714599

Somi Ozaki, Kotaro Miyao, Sohei Yamamoto, Tomoyoshi Wakayama, Masaya Numata, Kenta Motegi, Hitomi Sawa, Toshiyasu Sakai, Yuichiro Inagaki, Masashi Sawa

引用次数: 0

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma. 多发性骨髓瘤中与t细胞接合体相关的感染的特征和预后意义。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-11 DOI: 10.1080/10428194.2026.2714341

Lindsay Fogel, Harsh Parmar, Shucen Wan, Pooja Phull, Kimberly Doucette, Adolfo Aleman, Palka Anand, Joseph Franz, David Vesole, David Siegel, Noa Biran

引用次数: 0

Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. 系统的文献综述了阿昔巴他基西鲁治疗复发/难治性大b细胞淋巴瘤的临床结果、健康相关生活质量、医疗成本和资源使用。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-27 DOI: 10.1080/10428194.2026.2695323

Yi Lin, Madhu Palivela, Pardis Lakzadeh, Eve Limbrick-Oldfield, Sally W Wade, Hil Hsu, Steve Kanters, Robin Sanderson

{"title":"Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.","authors":"Yi Lin, Madhu Palivela, Pardis Lakzadeh, Eve Limbrick-Oldfield, Sally W Wade, Hil Hsu, Steve Kanters, Robin Sanderson","doi":"10.1080/10428194.2026.2695323","DOIUrl":"10.1080/10428194.2026.2695323","url":null,"abstract":"The approval of axicabtagene ciloleucel (axi-cel) for use in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emerging real-world evidence provides clinical and economic insights. We conducted a systematic review of studies reporting such outcomes among patients with treated with axi-cel in 2L and 2L + R/R LBCL. In routine care, axi-cel shows effectiveness comparable to clinical trials, with a lower rate of serious cytokine release syndrome in real-world 2L populations. Most real-world studies reported similar or lower incidence of neurological complications despite their broader populations. Patient-reported data indicate an early, transient health-related quality of life (HRQoL) decline followed by improvements over baseline in multiple domains. HRQoL gains were consistent with or exceeded trial results. Early economic analyses suggest that outpatient administration may offer a lower-cost option than inpatient infusions for some patients. Overall, these findings inform healthcare decision-making and support the use of axi-cel in routine clinical practice.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2266-2281"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera. 干扰素α -2b对真性红细胞增多症低、高危患者放血效果的交叉研究分析

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-17 DOI: 10.1080/10428194.2026.2699995

Anthony Michael Hunter, Albert Qin, Lucia Masarova, Ghaith Abu-Zeinah, Sung-Eun Lee, Ji Yun Lee, Jie Jin, Zhang Lei, Keita Kirito, Kazuya Shimoda, Toshiaki Sato, Daoxiang Wu, Yun Lee, Han Chiu, Abdulraheem Yacoub, Norio Komatsu, Ruben Mesa

{"title":"Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.","authors":"Anthony Michael Hunter, Albert Qin, Lucia Masarova, Ghaith Abu-Zeinah, Sung-Eun Lee, Ji Yun Lee, Jie Jin, Zhang Lei, Keita Kirito, Kazuya Shimoda, Toshiaki Sato, Daoxiang Wu, Yun Lee, Han Chiu, Abdulraheem Yacoub, Norio Komatsu, Ruben Mesa","doi":"10.1080/10428194.2026.2699995","DOIUrl":"10.1080/10428194.2026.2699995","url":null,"abstract":"Therapeutic phlebotomy maintains hematocrit (Hct) <45% in patients with polycythemia vera (PV) and reduces thrombotic risks. However, frequent phlebotomy can induce iron deficiency. Ropeginterferon alfa-2b (ropeg) is a new-generation interferon therapy that induces durable complete hematologic and molecular responses through reduction of the Janus kinase 2 (JAK2)-mutated clone. Two dosing regimens have been investigated: the FDA-approved slow-titration regimen and a higher initial dose and accelerated titration (HIDAT) regimen. A cross-analysis of three prospective trials showed that ropeg achieved sustained Hct control and reduction of phlebotomy dependence in PV patients, including high-risk and hydroxyurea-resistant/intolerant patients. In exploratory cross-study comparisons, the HIDAT regimen was associated with more rapid phlebotomy-free Hct response rates, lower mean annualized phlebotomy frequency, higher overall hematologic response rates and deeper JAK2V617F allele burden reduction than slow titration. Both regimens were safe and well tolerated. Ropeg treatment provides durable Hct control and phlebotomy-independence in a broad PV population, including high-risk patients.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2313-2326"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a FLT3 N676K variant. 在FLT3 N676K变异的复发性AML中，对补救性吉特替尼、同种异体干细胞拯救和维持治疗的持久反应

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-07 DOI: 10.1080/10428194.2026.2697465

Samuel Grigg, Amit Khot, Andrew H Wei

引用次数: 0

Transfusion-Independent iron overload in SF3B1-mutant myelodysplastic syndrome case report. sf3b1突变骨髓增生异常综合征患者输血不依赖铁超载病例报告。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-28 DOI: 10.1080/10428194.2026.2707444

Ashik Zala, Simone Claudiani, Simona Deplano

引用次数: 0

CD74 in hematological malignancies: from MHC chaperone to therapeutic target. CD74在血液恶性肿瘤中的作用：从MHC伴侣到治疗靶点。